Berlin, Germany

Christoph Philipp Hethey

This inventor holds 1 USPTO granted patent. Top assignee: Bayer Aktiengesellschaft. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Christoph Philipp Hethey. Retrieved from https://idiyas.com/inventor/christoph-philipp-hethey

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 14.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Christoph Philipp Hethey: Inventor of SOS1 Inhibitor Compounds.

Introduction

Christoph Philipp Hethey is an inventor based in Berlin, Germany, associated with Bayer Aktiengesellschaft. His work includes a patent concerning phosphorus derivatives developed as SOS1 inhibitors.

Latest Patents

Hethey is credited with 1 patent: “Phosphorus Derivatives as SOS1 Inhibitors.” The invention covers phosphorus derivatives, methods for preparing them, useful intermediate compounds, and pharmaceutical compositions and combinations containing them. It also describes using these compounds to manufacture medicines for treating or preventing diseases, particularly hyperproliferative disorders associated with SOS1, either alone or alongside other active ingredients.

Career Highlights

Hethey’s listed patent work is connected to pharmaceutical research at Bayer Aktiengesellschaft. The patent focuses on compounds and potential therapeutic applications involving SOS1.

Collaborations

Felix Pape and Benjamin Bader are identified as Hethey’s coworkers.

Conclusion

Christoph Philipp Hethey’s patent contribution centers on phosphorus-based SOS1 inhibitors and their potential use in pharmaceutical treatments.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…